PHARMACOECONOMIC EFFECTIVENESS OF SOME MODERN METHODS OF THERAPY IN CYSTIC FIBROSIS CHILDREN

Abstract

In the last years interest has been aroused to pharmacoeconomics — the economic evaluation of treatment effectiveness. The investigation objective was the study of clinical effectiveness and the cost expediency of the inclusion of some modern drugs and medical technologies in the complex therapy of cystic fibrosis (CF) in children for the last decade in moscow. 105 patients during the period from 1993 to 2004 were investigated. Within this span of time some drugs were included: substitutive micros pheric pancreatic enzymes (Kreon) — 1993, mucolytic agent dornase alfa (Pulmozyme) and antibiotic ceftazidime — 1998, antibiotics cefepime and meropenem — 2003. since 1998 patients began to receive planned domiciliary intravenous therapy by antibiotics. The introduction of new drugs and medical technics (intravenous antibacterial therapy at home) caused increase of life expectancy of patients with CF from 16 to 27,9 years. The annual cost of therapy was in 1993 — 1809.8, in 1998 — 4266.7, and in 2003 — 23830.8 US dollars. Severity, age of patients, and pseudomonas infection were the decisive factors in the treatment cost.
Key words: cystic fibrosis, pharmacoeconomics, therapy, life expectancy.